Tag - LPCN

Markets

Cantor starts Lipocine at OW; PT $3

Cantor Fitzgerald initiated coverage of Lipocine (NASDAQ:LPCN) with an “overweight” rating and 12-month price target of $3. The stock closed at $1.36 on June 23. “We think Lipocine has multiple shots on goal across its...

June 24, 2021

Feature

FDA advisory vote on TLANDO not a knockout for Lipocine

By Len Zehrs Although Lipocine (NASDAQ:LPCN) is disappointed by a FDA advisory committee vote against the benefit/risk profile of TLANDO, its oral testosterone replacement therapy (TRT), the company believes there is...

January 23, 2018

Feature

Lipocine advancing pipeline, PDUFA for oral TRT

By Len Zehr With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing...

May 31, 2016

Tag - LPCN

Cantor starts Lipocine at OW; PT $3

FDA advisory vote on TLANDO not a knockout for Lipocine

Lipocine advancing pipeline, PDUFA for oral TRT

General

More